Antibody drug names end in -mab. Learn the target, the use and the major risk.
Common targets
- TNF-alpha: infliximab, adalimumab, etanercept (latent TB reactivation; screen before starting).
- CD20: rituximab (B cell lymphoma, rheumatoid arthritis; hepatitis B reactivation).
- HER2: trastuzumab (cardiotoxicity).
- VEGF: bevacizumab (impaired wound healing, hemorrhage).
- EGFR: cetuximab (rash).
- IgE: omalizumab.
- IL-6 receptor: tocilizumab.
- RANKL: denosumab.
- PCSK9: evolocumab.
Checkpoint inhibitors
Block CTLA-4 (ipilimumab) or PD-1 and PD-L1 (nivolumab, pembrolizumab) and release T cells against tumors. Adverse effects are immune related: colitis, pneumonitis, hepatitis, thyroid and adrenal disease.
Safety
Biologics raise infection risk. Check hepatitis B and tuberculosis status first; avoid live vaccines.
Keep going in immunology
- Laboratory tests: ELISA, Western blot, PCR and flow cytometry
- Hypersensitivity reactions: types I, II, III and IV
- Primary immunodeficiencies: Bruton, SCID, DiGeorge and CVID
- MHC, T cell activation and cytokines